Please login to the form below

Not currently logged in

NICE recommendation

This page shows the latest NICE recommendation news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca wins NICE backing for asthma injection

AstraZeneca wins NICE backing for asthma injection

The recommendation from England's cost effectiveness watchdog gives AZ's injection a toe-hold in the market, where GSK's Nucala and Teva's Cinqaero are already NICE-approved. . ... But the revised offer from AstraZeneca has led to  a broader

Latest news

More from news
Approximately 2 fully matching, plus 116 partially matching documents found.

Latest Intelligence

  • Positive disruption in business intelligence Positive disruption in business intelligence

    Take the recent recommendation by NICE, the UK’s drug-spending policymaker, of Kadcyla, the breast cancer treatment launched by Roche. ... In December 2016, NICE issued draft guidance indicating Kadcyla was too expensive for routine funding on the NHS.

  • Rare diseases: meeting the challenge Rare diseases: meeting the challenge

    Companies will still need to work hard to win a NICE ‘yes’ recommendation, and may still yet have to accept optimised - as NICE calls them - or restricted - as industry calls them - ... None of the four therapies approved to date under the NICE HST

  • The death of the cancer drugs fund? The death of the cancer drugs fund?

    evidence to support a recommendation for routine commissioning, and where additional evidence would be likely to enable a more informed NICE appraisal decision. ... positive recommendation at which point it would move out of the Fund into mainstream

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    She gives the example of a drug to prevent a second heart attack that has a positive NICE recommendation, can save people's lives and reduce further hospital costs. ... It sounds like good value and NICE has also said it is,” says Anson.

  • Creating a 21st century life sciences ecosystem Creating a 21st century life sciences ecosystem

    England's health technology assessor NICE, which decides which drugs the NHS should pay for. ... So, where you do get a licensing approval, then a NICE recommendation, there isn't such a long delay to get uptake.".

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...